Kedrion Advocates for Early Diagnosis of Secondary Immunodeficiencies at ESID 2026

Introduction

At the recent ESID 2026 conference in Maastricht, a critical dialogue was held among healthcare professionals about the rising prevalence of Secondary Immunodeficiencies (SIDs). Experts underscored the pressing need for a shift in approach towards these often overlooked conditions to ensure timely diagnoses and improved patient outcomes.

The Growing Challenge of Secondary Immunodeficiencies

Secondary immunodeficiencies (SIDs) pose a global healthcare challenge that is frequently underestimated. With the increased use of immunosuppressive therapies and biologics in clinical settings, along with better treatment options for hematological malignancies, the incidence of SIDs is likely to rise. Many patients are affected by diseases that lead to acquired immune dysfunctions, amplifying the necessity for awareness and improved diagnostic practices.

Despite notable advancements in medical science, SIDs often remain underdiagnosed or are recognized only at advanced stages. This delay can result in serious health complications such as recurrent infections, prolonged hospital stays, diminished quality of life, and other preventable issues. Therefore, the adoption of strategies that enhance awareness, promote early diagnosis, and standardize treatment protocols became focal points of discussions at the conference.

Voices from the Conference

Johan Prevot, the Executive Director of the International Patient Organization for Primary Immunodeficiencies (IPOPI), emphasized the global disparities in awareness, diagnosis, and patient care pertaining to SIDs. He stated, "Despite gaining traction in the healthcare community, there remain significant gaps across different nations. A considerable number of SID patients may actually have undiagnosed Primary Immunodeficiencies (PIDs) that need to be recognized and treated properly."

Adding to these concerns, Dr. Silvia Sánchez-Ramón, head of the Immunology Department at La Paz University Hospital in Madrid, noted advancements in recognizing secondary immunodeficiencies but warned that substantial gaps still exist. She urged for early detection strategies, interdisciplinary collaboration, and broader application of evidence-based practices to ensure patients receive timely treatment.

Gorana Dasic, Vice President and Global Medical Affairs Head at Kedrion Biopharma, stressed the importance of strong multidisciplinary cooperation in tackling the challenges posed by SIDs. "Clinical advancements depend on robust connections between science, clinical practice, and patient experiences. Kedrion is committed to fostering networks and knowledge that contribute to earlier diagnoses and better-informed treatments through research collaborations and patient-centered projects."

Kedrion's Contributions at ESID 2026

At ESID 2026, Kedrion presented two pivotal posters: one addressing safety data related to immunoglobulin therapy and the other highlighting the MAPPA survey initiative and its international expansion. Clinicians and healthcare professionals were invited to engage at Kedrion's booth, facilitating discussions on clinical practices and patient experiences related to immunodeficiencies.

The MAPPA survey, developed by the Italian Association for Primary Immunodeficiencies (AIP APS) in collaboration with Kedrion, captures insights from individuals with primary immunodeficiencies across Europe. This project reflects Kedrion's commitment to strengthening ties with patient organizations and amplifying the patient's voice in healthcare discussions.

Preliminary Insights from MAPPA

Preliminary results from the MAPPA initiative revealed alarming trends regarding the delays in diagnosis, with over half of participants reporting their diagnosis came after the age of 18. Additionally, 28% noted suffering from lasting damage by the time they were diagnosed. Such findings underscore the critical need for heightened awareness and efficient diagnostic practices to support those living with these conditions.

Alessandro Segato, President of AIP APS, reinforced the importance of empowering patients to share their real-life experiences as invaluable resources for knowledge generation. He noted that the integration of these experiences into evidence can illuminate shared needs and challenges that might otherwise go unnoticed.

Conclusion

For Kedrion, expanding knowledge remains a vital step in addressing the evolving global challenges posed by primary and secondary immunodeficiencies. By fostering collaboration, promoting awareness, and encouraging timely diagnostics, the healthcare community can make significant strides in improving outcomes for patients impacted by these conditions.

For more information, visit www.kedrion.com.